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cytoreduction, and because of the potential difﬁculties associated
with subsequent removal of the gastric band after IP chemotherapy,
the device was removed. The omentum and gastric band tubing
were mobilised, the lesser sac was entered and the gastro-
oesophageal junction identiﬁed. The band was released and cut (see
Fig. 1) and the subcutaneous Infusaport section of the device was
retained and converted into an IP port (see Fig. 2). During closure, the
retained Infusaport was tested for peritoneal infusion using heparinised
saline. At the conclusion of the surgery the residual disease was 0.5 cm
of miliary tumour.carcinomaof the ovary. The patient successfully completed 6 cycles of IPIntroduction
Intraperitoneal (IP) chemotherapy in women with optimally
debulked stage 3 ovarian cancer improves overall survival and
progression-free survival, and its use has been encouraged in the adju-
vant treatment of appropriately selected patients (Armstrong et al.,
2006; Jaaback and Johnson, 2006).We describe a case in which a previ-
ously inserted adjustable gastric band was converted to an IP chemo-
therapy port during a laparotomy for advanced ovarian cancer.Case report
A 44 year old woman was referred with suspected metastatic ovari-
an cancer and ascites. Her past medical history included a laparoscopy
and insertion of an adjustable gastric band 12 years earlier, and total
hysterectomy and right salpingo-oophorectomy 6 years earlier for be-
nign disease.
At laparotomy there was a 3 cm left ovarian mass with pelvic side
wall and left ureteric involvement, large volume omental tumour and
extensive miliary peritoneal disease. Adhesiolysis and ureterolysis
were performed followed by left infundibulopelvic ligament ligation
and a radical left salpingo-oophorectomy. Frozen section reported an
adenocarcinoma of ovarian origin. On assessment of the upper
abdomen, the intraperitoneal tubing of the gastric band was encasedr), Paul.Cohen@sjog.org.au
m (J. Tan).
. This is an open access article underHistopathology conﬁrmed a FIGO stage 3C, high grade serous adeno-
Cisplatin 135 mg, IP Paclitaxel 125 mg and intravenous Paclitaxel
225 mg without any adverse effects or delays in treatment. There
were no difﬁculties in accessing the converted gastric band Infusaport,
however it varied from other IP ports in that it's bulb was located
more deeply within the subcutaneous tissue and required a two ﬁnger
stabilisation technique for use. The port was removed after completion
of chemotherapy (see Fig. 3) and histopathology conﬁrmed no seeding
of tumour along the tubing.
Discussion
Obesity is a public health issue of epidemic proportions and there is a
well-recognised association between obesity and certain ovarian cancer
subtypes (Olsen et al., 2013). As the number of bariatric surgical proce-
dures increases in line with obesity rates, gynecologic oncologists may
more frequently encounter gastric bands at laparotomy in patients
with advanced ovarian cancer. Abdominal complaints after bariatric
surgery, such as weight gain, dyspepsia and distension, are often ex-
plained by surgical complications or poor eating habits. However, in a
middle-aged woman who presents with abdominal distension follow-
ing a gastric banding procedure, ovarian disorders must be considered
in the differential diagnosis (Tenhagen et al., 2012).
The decision to separate the subcutaneous Infusaport from the in-
ﬂatable band piece and convert it to an IP port at the time of surgery
spared our patient further surgery and the need for a new port. The re-
moval of the adjustable part of the band was essential to eliminate the
risk of future complications, such as gastric erosion or slippage (Snow
and Severson, 2011), which would be difﬁcult to manage surgically fol-
lowing intraperitoneal chemotherapy due to the high likelihood of
adhesions.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Removed portion of gastric band. Fig. 3. Infusaport portion of gastric band following removal.
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cytoreduction and the histopathology conﬁrmed that the tissue adher-
ent to the band contained malignant cells. Leaving the Infusaport in
situ may carry a potential risk of subcutaneous metastasis as malignant
cells may have seeded along the tubing to the subcutaneous tissues ad-
jacent to the Infusaport. The patient's Infusaport site will be monitored
closely for this during her follow-up.Fig. 2. Schematic diagram of the procedure.This is the ﬁrst reported case of a gastric band being adherent to
upper abdominal metastases from an ovarian carcinoma and describes
a novel technique of conversion of a gastric band to an IP chemotherapy
port.
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